NKGen Biotech, Inc. Common Stock (NKGN) Earnings History
Annual and quarterly earnings data from 2021 to 2024
Loading earnings history...
NKGN EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
NKGN Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | 76.6% | -31618.2% | -34745.5% |
| 2021 | 93.0% | -5131.7% | -5461.3% |
Download Data
Export NKGN earnings history in CSV or JSON format
Free sign-in required to download data
NKGen Biotech, Inc. Common Stock (NKGN) Earnings Overview
As of May 8, 2026, NKGen Biotech, Inc. Common Stock (NKGN) reported trailing twelve-month net income of -$24M, reflecting +71.4% year-over-year growth. The company earned $-0.82 per diluted share over the past four quarters.
Looking at the long-term picture, NKGN's historical earnings data spans multiple years. The company achieved its highest annual net income of -$23M in fiscal 2021.
NKGen Biotech, Inc. Common Stock is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including FATE (-$136M net income, -2051.1% margin), NKTX (-$103M net income), CELC (-$163M net income), NKGN has comparable earnings metrics. Compare NKGN vs FATE →
NKGN Earnings vs Peers
Earnings metrics vs comparable public companies
NKGN Historical Earnings Data (2021–2024)
4 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | -$44M | +46.6% | -$27M | $-1.54 | - | - |
| 2023 | -$83M | -210.1% | -$30M | $-5.38 | - | - |
| 2022 | -$27M | -15.0% | -$24M | $-1.25 | -34745.5% | -31618.2% |
| 2021 | -$23M | - | -$22M | $-1.08 | -5461.3% | -5131.7% |
See NKGN's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs NKGN Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare NKGN vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonNKGN — Frequently Asked Questions
Quick answers to the most common questions about buying NKGN stock.
Is NKGN growing earnings?
NKGN EPS is $-0.82, with earnings growth accelerating to +71.4%. This exceeds the 5-year CAGR of N/A. TTM net income reached $-24M.
What are NKGN's profit margins?
NKGen Biotech, Inc. Common Stock net margin is N/A, with operating margin at N/A. Below-average margins reflect competitive or cost pressures.
How consistent are NKGN's earnings?
NKGN earnings data spans 2021-2024. The accelerating earnings trend is +71.4% YoY. Historical data enables comparison across business cycles.